Year 2020
Stage I. Synthesis and characterization of the precursors
Task I.1. Synthesis and characterization of oligochitosan
Task I.2. Synthesis and characterization of synthetic copolymer
Year 2021
Stage II. Design, synthesis and characterization of peptide-functionalized magnetic nanocarriers loaded with dexamethasone
Task II.1. Functionalization of oligochitosan with the peptides
Task II.2. Preparation of characterization of magnetic nanoparticles
Task II.3. Preparation of peptide-functionalized magnetic nanocapsules loaded with dexamethasone
Task II.4. Preparation of peptide-functionalized magnetic liposomes loaded with dexamethasone
Task II.5. Physico-chemical characterization of peptide-functionalized NPs
Year 2022
Stage III. In vitro behaviour of peptide-functionalized magnetic nanocarriers loaded with dexamethasone
Task III.1. Preparation of fluorescent peptides-functionalized magnetic nanocarriers
Task III.2. In vitro drug release studies
Task III.3. Evaluation of the in vitro drug delivery to the inner ear using an artificial mucosa model
Task III.4. Biodegradability studies of oligochitosan-based nanocarriers
Task III.5. Assessment of the in vitro cytotoxicity
Year 2023
Stage IV. In vitro investigation of protein adsorption, hemocompatibility and behaviour of the peptide-functionalized magnetic nanocarriers at the cellular level
Task IV.1. Protein adsorption studies
Task IV.2. In vitro assessment of the interaction of peptide-functionalized magnetic nanocarriers with the blood components
Task IV.3. In vitro cell viability assessment on various cell lines
Task IV.4. In vitro membranary cellular uptake estimation of drug-loaded nanocarriers
Task IV.5. Evaluation of anti-inflammatory activity of peptide-functionalized magnetic NPs on in vitro models
Year 2024
Stage V. In vitro investigation of hemocompatibility
Task IV.1. Hemocompatibility tests
https://uefiscdi.gov.ro/eea-norway-grants-en
Working together for a green, competitive and inclusive Europe